Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.

ABSTRACT: A precision medicine approach is appealing for use in AML due to ease of access to tumor samples and the significant variability in the patients' response to treatment. Attempts to establish a precision medicine platform for AML, however, have been unsuccessful, at least in part due to the use of small compound panels and having relatively slow turn over rates, which restricts the scope of treatment and delays its onset. For this pilot study, we evaluated a cohort of 12 patients with refractory AML using an ex vivo drug sensitivity testing (DST) platform. Purified AML blasts were screened with a panel of 215 FDA-approved compounds and treatment response was evaluated after 72h of exposure. Drug sensitivity scoring was reported to the treating physician, and patients were then treated with

SUBMITTER: Swords RT 

PROVIDER: S-EPMC5756519 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature